-+ 0.00%
-+ 0.00%
-+ 0.00%

NRX PHARMACEUTICALS (NASDAQ:NRXP) ANNOUNCES 70,000 PATIENT DATA ON REAL WORLD USE OF KETAMINE FOR TREATMENT OF SUICIDAL DEPRESSION TO BE SUBMITTED TO THE FDA IN SUPPORT OF NRX-100 APPROVAL

Reuters·01/14/2026 12:03:00

Please log in to view news